Kanda Srishti, Chatha Uzair, Odoma Victor A, Pitliya Aakanksha, AlEdani Esraa M, Bhangu Japneet K, Javed Khalid, Manshahia Prabhleen Kaur, Nahar Shamsun, Hamid Pousette
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Medicine, Lahore Medical and Dental College, Lahore, PAK.
Cureus. 2023 Aug 26;15(8):e44166. doi: 10.7759/cureus.44166. eCollection 2023 Aug.
Metformin (MTF) is a commonly prescribed medication for women with polycystic ovarian syndrome (PCOS), but its impact on pregnancy outcomes in women with PCOS remains controversial. This systematic review aims to evaluate the effects of MTF intervention on pregnancy outcomes in women with PCOS and the impact of MTF on offspring. A comprehensive search is conducted in PubMed, Google Scholar, and ScienceDirect databases from 2019 up to May 16, 2023. Only review articles and meta-analyses are included, focusing on women with PCOS who received MTF during pregnancy or as part of infertility treatment. The primary outcomes of interest are clinical pregnancy rate (CPR), miscarriage rate, preterm birth rate, and live birth rate. Secondary outcomes are the safety profile of MTF. Data extraction and quality assessment are performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the assessment using the multiple systematic reviews (AMSTAR) 2 tool, respectively. The initial search produced 1877 studies. Thirteen studies were included in the review. While the use of MTF during pregnancy in women with PCOS may have some benefits in reducing certain pregnancy complications such as pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM), preeclampsia, preterm delivery, reducing the risk of ovarian hyperstimulation syndrome (OHSS) in women with PCOS undergoing in vitro fertilization (IVF); however, there is no significant difference in clinical pregnancy and live birth rates overall, but subgroup analysis suggests potential benefits for women with a higher body mass index (BMI). MTF is associated with a larger fetal head circumference and potential long-term effects on offspring's BMI and obesity. Further research is needed to better understand the optimal dosing of MTF, long-term effects, and effects in specific subgroups. The heterogeneity of the included studies limited the ability to analyze the data effectively, leading to challenges in drawing definitive conclusions.
二甲双胍(MTF)是多囊卵巢综合征(PCOS)女性常用的处方药,但其对PCOS女性妊娠结局的影响仍存在争议。本系统评价旨在评估MTF干预对PCOS女性妊娠结局的影响以及MTF对后代的影响。对2019年至2023年5月16日期间的PubMed、谷歌学术和ScienceDirect数据库进行了全面检索。仅纳入综述文章和荟萃分析,重点关注在孕期或作为不孕症治疗一部分接受MTF的PCOS女性。感兴趣的主要结局是临床妊娠率(CPR)、流产率、早产率和活产率。次要结局是MTF的安全性。分别按照系统评价和荟萃分析的首选报告项目(PRISMA)指南以及使用多重系统评价(AMSTAR)2工具进行数据提取和质量评估。初步检索产生了1877项研究。本综述纳入了13项研究。虽然PCOS女性孕期使用MTF可能在降低某些妊娠并发症方面有一些益处,如妊娠高血压(PIH)、妊娠期糖尿病(GDM)、先兆子痫、早产,降低接受体外受精(IVF)的PCOS女性发生卵巢过度刺激综合征(OHSS)的风险;然而,总体临床妊娠率和活产率没有显著差异,但亚组分析表明对体重指数(BMI)较高的女性可能有益。MTF与较大的胎儿头围相关,并且对后代的BMI和肥胖可能有长期影响。需要进一步研究以更好地了解MTF的最佳剂量、长期影响以及在特定亚组中的影响。纳入研究的异质性限制了有效分析数据的能力,导致得出明确结论存在挑战。